The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 04, 2017

Filed:

Nov. 22, 2011
Applicant:

Cynthia L. Bristow, New York, NY (US);

Inventor:

Cynthia L. Bristow, New York, NY (US);

Assignees:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/04 (2006.01); A61K 38/48 (2006.01); A61K 38/16 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
G01N 33/5047 (2013.01); G01N 2333/95 (2013.01); G01N 2800/52 (2013.01);
Abstract

A previously unrecognized fundamental property of αProteinase Inhibitor (αPI) is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified αPI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with HIV-1 infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of αPI with its receptors, Human Leukocyte Elastase Cell Surface (HLE) and Low Density Lipoprotein-Receptor Related Protein (LRP), influences the level of cells of different lineages. Genetic and proteolytic modification of αPI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.


Find Patent Forward Citations

Loading…